NCT02621151View on ClinicalTrials.gov

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 11, 2016

Primary Completion Date

November 10, 2022

Study Completion Date

December 31, 2025

Conditions
Muscle-invasive Urothelial Cancer of the Bladder
Interventions
BIOLOGICAL

Pembrolizumab

PROCEDURE

Transurethral Resection of Bladder Tumor

DRUG

Gemcitabine

RADIATION

External Beam Radiation Therapy

Trial Locations (5)

10016

NYU Perlmutter Cancer Center, New York

10065

Memorial Sloan Kettering, New York

48109

University of Michigan Health System, Ann Arbor

60637

University of Chicago, Chicago

27599-7305

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

NYU Langone Health

OTHER